Literature DB >> 8180383

Functional and binding studies of the roles of prothrombin and beta 2-glycoprotein I in the expression of lupus anticoagulant activity.

P Permpikul1, L V Rao, S I Rapaport.   

Abstract

We present functional and binding data relevant to the reported roles for prothrombin and beta 2-glycoprotein I (beta 2GPI) in the expression of lupus anticoagulant activity. In a purified system containing human prothrombin, Xa, Va, and a rate-limiting concentration of phosphatidylserine (PS)/phosphatidylcholine (PC) vesicles, the preliminary incubation of vesicles with protein A separated IgG preparations from 10 lupus anticoagulant plasmas, calcium, and prothrombin enhanced the inhibitory effect of all IgG preparations upon thrombin generation. Experiments in a purified factor X activation system provided supporting data that a similar preliminary incubation with prothrombin enhanced the inhibitory effect of many of the IgG preparations upon factor X activation. However, we could not obtain unequivocal evidence that prothrombin was an obligatory cofactor for lupus anticoagulant IgG to inhibit procoagulant phospholipid function, because lupus anticoagulant IgG separated by protein A chromatography contained traces of prothrombin. The binding of many IgG preparations to immobilized PS was enhanced by prothrombin when calcium ions were present. beta 2GPI enhanced binding of many of the IgG preparations to immobilized PS both in the presence and absence of calcium, yet beta 2GPI failed to enhance the ability of the IgG preparations to inhibit phospholipid function in purified prothrombin and factor X assays. Moreover, the IgG preparations prolonged the dilute Russell's viper venom time (dRVVT) of beta 2GPI-depleted normal plasma. Nine of 10 IgG preparations bound to prothrombin on Western blots in the absence of calcium and phospholipid, whereas no preparation bound to beta 2GPI. Passage of five citrated lupus anticoagulant plasmas through a prothrombin affinity column in the absence of added calcium and phospholipid removed most of the activity prolonging the dRVVT of normal plasma, and IgG in the pass-through plasma no longer bound to PS in the presence of prothrombin and calcium ions. IgG in prothrombin column eluates had strikingly enhanced specific lupus anticoagulant activity and also specific PS binding activity in the presence of prothrombin and calcium ions. Thus, lupus anticoagulant plasmas were shown to contain IgG binding to prothrombin, in the absence of calcium ions and phospholipid, which could also, in the presence of calcium ions and prothrombin, bind to PS and express lupus anticoagulant activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8180383

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Binding properties of antibodies to prothrombin and beta2-glycoprotein I (beta2-GPI) assayed by ELISA and dot blot.

Authors:  R R Forastiero; M E Martinuzzo; L O Carreras
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1 (and other proteins).

Authors:  S Hörkkö; E Miller; D W Branch; W Palinski; J L Witztum
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

3.  Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids.

Authors:  H Takeya; T Mori; E C Gabazza; K Kuroda; H Deguchi; E Matsuura; K Ichikawa; T Koike; K Suzuki
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

Review 4.  Antibodies to serine proteases in the antiphospholipid syndrome.

Authors:  Pojen P Chen; Ian Giles
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

5.  Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo.

Authors:  Zurina Romay-Penabad; Maria Guadalupe Montiel-Manzano; Tuya Shilagard; Elizabeth Papalardo; Gracie Vargas; Arun B Deora; Michael Wang; Andrew T Jacovina; Ethel Garcia-Latorre; Elba Reyes-Maldonado; Katherine A Hajjar; Silvia S Pierangeli
Journal:  Blood       Date:  2009-07-23       Impact factor: 22.113

6.  A Study of Anti Beta-2 Glycoprotein I and Anti-Prothrombin Antibodies in Patients with Unexplained Recurrent Pregnancy Losses.

Authors:  Angad Singh; Anita Nangia; Sunita Sharma; Manju Puri
Journal:  Indian J Hematol Blood Transfus       Date:  2015-04-03       Impact factor: 0.900

7.  Standardized measurement of major immunoglobulin class (IgG, IgA, and IgM) antibodies to beta2glycoprotein I in patients with antiphospholipid syndrome.

Authors:  S Lewis; L B Keil; W L Binder; V A DeBari
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

8.  Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases.

Authors:  Wei-Shiang Lin; Pei-Chih Chen; Cheng-De Yang; EunJung Cho; Bevra H Hahn; Jennifer Grossman; Kwan-Ki Hwang; Pojen P Chen
Journal:  Arthritis Rheum       Date:  2007-05

Review 9.  Pathophysiology of the antiphospholipid antibody syndrome.

Authors:  Rohan Willis; Silvia S Pierangeli
Journal:  Auto Immun Highlights       Date:  2011-03-24

Review 10.  Antiphospholipid antibodies: paradigm in transition.

Authors:  Lawrence L Horstman; Wenche Jy; Carlos J Bidot; Yeon S Ahn; Roger E Kelley; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; Seyed Ali Mousavi; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2009-01-20       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.